Nicox S.A., a prominent player in the health care biotechnology sector, has been making significant strides in the development and marketing of therapies targeting ophthalmic conditions. Headquartered in Valbonne, France, Nicox has established itself as a key innovator in the field, with a robust product pipeline and strategic collaborations that underscore its commitment to advancing eye care.
As of December 3, 2025, Nicox’s stock closed at 0.304 EUR, reflecting a challenging market environment. The company’s 52-week high was recorded at 0.65 EUR on August 6, 2025, while its low was 0.2 EUR on April 6, 2025. Despite these fluctuations, Nicox maintains a market capitalization of 24,940,000 EUR, indicative of its enduring presence in the biotechnology landscape.
Nicox’s product pipeline is diverse and innovative, featuring several promising candidates. Vyzulta™, an intraocular pressure-lowering treatment, stands out as a significant advancement in glaucoma management. Additionally, NCX 470, a nitric oxide (NO)-donating candidate, is under development for glaucoma treatment, showcasing Nicox’s focus on novel therapeutic approaches. The company also explores stand-alone NO donors for specific ophthalmic applications, further expanding its therapeutic reach.
ZERVIATE, an eye drop formulation of cetirizine, addresses allergic conjunctivitis, providing relief for patients suffering from this common condition. NCX 4280, an ophthalmic solution targeting morning ocular congestion, and NCX 4251, a patented formulation of fluticasone propionate for blepharitis, complete Nicox’s diverse portfolio, highlighting its commitment to addressing a wide range of ophthalmic issues.
Strategic collaborations have been a cornerstone of Nicox’s success. The company has forged partnerships with industry giants such as Bausch + Lomb, AstraZeneca, Merck, Pfizer, and Ironwood Pharmaceuticals, Inc., as well as Novaliq GmbH. These alliances not only enhance Nicox’s research and development capabilities but also facilitate the global reach of its innovative therapies.
Founded in 1996, Nicox has grown from a nascent biotechnology firm to a key player in the ophthalmic sector. Its dual listing on the NYSE and Euronext Paris stock exchanges underscores its international presence and investor confidence. As Nicox continues to navigate the complexities of the biotechnology industry, its focus on innovation, strategic partnerships, and a diverse product pipeline positions it well for future growth and success in the global health care market.
For more information about Nicox and its ongoing initiatives, stakeholders and interested parties are encouraged to visit the company’s website at www.nicox.com .
